In the latest trading session, Amgen (AMGN) closed at $277.29, marking a -1.89% move from the previous day. This change lagged the S&P 500's 0.13% gain on the day. At the same time, the Dow lost 1.33% ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

Shares of UnitedHealth and Amgen are posting losses Thursday morning, propelling the Dow Jones Industrial Average selloff. The Dow was most recently trading 499 points, or 1.3%, lower, as shares of ...

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Despite resilient demand, healthcare has taken a hit along with the rest of the market. Amgen could boost profits ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...

Big Pharma and biotech startups alike are counting on AI to speed the process of drug discovery and make their operations ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sandoz ...